Skip to content

Development of a VR module for relapse prevention in depressive symptomatology using eye tracking-based markers.

Development of a VR module for relapse prevention in depressive symptomatology using eye tracking-based markers. - DeepTrack

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00024775
Enrollment
120
Registered
2021-03-17
Start date
2021-05-06
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33 F34 F43.2

Interventions

Group 1: Viewing faces in VR (patients with depression symptomatology/sick people) Group 2: Viewing faces in VR (healthy subjects/control group)

Sponsors

Universitätsklinikum Düsseldorf, Klinisches Institut für Psychosomatische Medizin und Psychotherapie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients (m/f/d) with depressive symptoms (depression diagnosis , ICD-10: F32-F34 or F 43.2) aged 18 to 70 years as well as control subjects without depressive symptoms, also aged 18-70 years. Depression symptomatology will be assessed via the study questionnaires (PHQ-2, BDI-II), subjects who do not reach the cut-off value will be assigned to the control group.

Exclusion criteria

Exclusion criteria: - COVID-19 disease in infectious phase or symptoms suggestive of COVID-19 disease. - Employee of the Clinical Institute of Psychosomatic Medicine and Psychotherapy. - Last alcohol consumption less than 8 hours ago - insufficient knowledge of the German language - uncorrected visual loss and visual disturbances - neurological/psychiatric pre-existing diseases, especially those affecting the vestibular organ impairing the sense of balance or altering visual perception - taking medications that affect eye movements (Lithium, carbamazepine, lamotrigine, topiramate, phenytoin, risperidone, haloperidol, phenobarbital, or primidone, and the use of benzodiazepines in the past 24 hours) - claustrophobia - prosopagnosia - a body mass index (BMI) less than or equal to 17

Design outcomes

Primary

MeasureTime frame
Total fixation time (TFT), measured with an Eyetracker included in the VR-glases during the experiment, physiological measurement

Secondary

MeasureTime frame
Number of fixations (NoF), measured with an Eyetracker included in the VR-glases during the experiment, physiological measurement

Countries

Germany

Contacts

Public ContactSteffen Holsteg

Universitätsklinikum Düsseldorf, Klinisches Institut für Psychosomatische Medizin und Psychotherapie

steffen.holsteg@med.uni-duesseldorf.de02118116211

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026